ARTICLE | Clinical News
Sinogliatin: Phase Ib data
February 16, 2015 8:00 AM UTC
A double-blind, placebo-controlled Phase Ib trial in 53 Type II diabetics showed that twice-daily 25, 50, 100, 150 and 200 mg doses of oral sinogliatin for 8 days were well tolerated with no severe ad...